Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.37 |
| ▸ | HPGD | P15428 | 3/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA7 | P43166 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | XDH | P47989 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5166036 | 0.83 | PDGFRB (0.40) | ALDH1A1TDP1KDM4EKMT2AMAPT | |
| SCHEMBL10362694 | 0.80 | KDM4E (0.53) | ALDH1A1HPGDTDP1CYP3A4KDM4E | |
| SCHEMBL9571700 | 0.80 | CA12 (0.42) | ALDH1A1HPGDTDP1CYP3A4CA12 | |
| SCHEMBL10364340 | 0.79 | MAPT (0.39) | ALDH1A1HPGDTDP1CYP3A4CA12 | |
| SCHEMBL7682549 | 0.78 | GAA (0.41) | ALDH1A1HPGDPOLBKMT2AGAA | |
| SCHEMBL20511627 | 0.78 | CA12 (0.47) | ALDH1A1HPGDTDP1CA12CA1 | |
| SCHEMBL2903057 | 0.78 | ALDH1A1 (0.39) | ALDH1A1HPGDCA12CA1CA2 | |
| SCHEMBL4248903 | 0.77 | KDM4E (0.56) | ALDH1A1HPGDTDP1CA12CA1 | |
| SCHEMBL24890918 | 0.75 | CA12 (0.41) | ALDH1A1HPGDTDP1CYP3A4CA12 | |
| SCHEMBL19113951 | 0.75 | GAA (0.58) | ALDH1A1HPGDTDP1CYP3A4CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120129876-A1 | [4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS AND METHODS RELATED THERETO | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120088736-A1 | [4-(6-HALO-7-Substituted-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS and Forms and Methods Related Thereto | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-20120009172-A1 | INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-8058284-B2 | [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-20090156620-A1 | [4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS AND METHODS RELATED THERETO | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090048216-A1 | INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090042916-A1 | [4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS AND METHODS RELATED THERETO | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-02-12 | — | — | US | disclosed |
| US-20070208045-A1 | SUBSTITUTED-(QUINAZOLINYL)PHENYL THIOPHENYL-SULFONYLUREAS, METHODS FOR MAKING AND INTERMEDIATES THEREOF | PORTOLA PHARMACEUTICALS, INC. (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070123547-A1 | [4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO | PORTOLA PHARMACEUTICALS, INC. (US) | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048216-A1 | INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR | P2RY12, P2RY11, P2RY13 | ALDH1A1 1886/4885HPGD 190/4885TDP1 1706/4885 |
| US-20090156620-A1 | [4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS AND METHODS RELATED THERETO | P2RY1, P2RY6, P2RY4 | ALDH1A1 712/4885HPGD 2483/4885TDP1 826/4885 |
| US-20090042916-A1 | [4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS AND METHODS RELATED THERETO | P2RY1, P2RY6, P2RY4 | ALDH1A1 712/4885HPGD 2483/4885TDP1 826/4885 |
| US-20120009172-A1 | INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR | P2RY12, P2RY11, P2RY13 | ALDH1A1 1886/4885HPGD 190/4885TDP1 1706/4885 |
| US-20070208045-A1 | SUBSTITUTED-(QUINAZOLINYL)PHENYL THIOPHENYL-SULFONYLUREAS, METHODS FOR MAKING AND INTERMEDIATES THEREOF | P2RY4, P2RY6, P2RY13 | ALDH1A1 925/4885HPGD 1160/4885TDP1 1301/4885 |
| US-20120088736-A1 | [4-(6-HALO-7-Substituted-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS and Forms and Methods Related Thereto | P2RX7, P2RY1, P2RY6 | ALDH1A1 1579/4885HPGD 2581/4885TDP1 718/4885 |
| US-20070123547-A1 | [4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO | P2RX7, P2RY1, P2RY6 | ALDH1A1 1579/4885HPGD 2581/4885TDP1 718/4885 |
| US-20120129876-A1 | [4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS AND METHODS RELATED THERETO | P2RY1, P2RY6, P2RY4 | ALDH1A1 712/4885HPGD 2483/4885TDP1 826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.